Read Gene

Read Gene Equity

The The Equity of Read Gene (RDG.WA) as of Nov 5, 2026 is 3.11 M PLN. In the previous year, The Equity was 3.02 M PLN — a change of 3.21% (higher).

Equity

3.11 MPLN

YoY

3.21%

Last updated:

In 2025, Read Gene's equity was 3.11 M PLN, a 3.21% increase from the 3.02 M PLN equity in the previous year.

The Read Gene Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.14 M PLN
Jan 1, 2019
3.24 M PLN
Jan 1, 2020
3.04 M PLN
Jan 1, 2021
5.42 M PLN
Jan 1, 2022
5.51 M PLN
Jan 1, 2023
4.16 M PLN
Jan 1, 2024
3.02 M PLN
Jan 1, 2025
3.11 M PLN
The Read Gene Equity history
YEAREquityYoY
3.11 MPLN+3.21%
3.02 MPLN-27.58%
4.16 MPLN-24.44%
5.51 MPLN+1.67%
5.42 MPLN+78.42%
3.04 MPLN-6.26%
3.24 MPLN+3.10%
3.14 MPLN+33.17%
2.36 MPLN-20.71%
2.98 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Read Gene's Equity

Read Gene's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Read Gene's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Read Gene's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Read Gene's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Read Gene’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Read Gene stock

The Equity of Read Gene is 3.11 M PLN in 2025.

The Equity of Read Gene changed from 3.02 M PLN to 3.11 M PLN, representing a 3.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Read Gene since 2006 – with annual values, charts, and detailed analysis.

The Equity's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Read Gene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Read Gene